2022
DOI: 10.3389/fnins.2022.998224
|View full text |Cite
|
Sign up to set email alerts
|

Predictors of response to acetylcholinesterase inhibitors in dementia: A systematic review

Abstract: BackgroundThe mainstay of therapy for many neurodegenerative dementias still relies on acetylcholinesterase inhibitors (AChEI); however, there is debate on various aspects of such treatment. A huge body of literature exists on possible predictors of response, but a comprehensive review is lacking. Therefore, our aim is to perform a systematic review of the predictors of response to AChEI in neurodegenerative dementias, providing a categorization and interpretation of the results.MethodsWe conducted a systemati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
11
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 16 publications
(11 citation statements)
references
References 159 publications
(331 reference statements)
0
11
0
Order By: Relevance
“…It was also not known whether long-term use would accompany desired outcomes, such as delay in institutionalization. It is now established that response to CIs is complex and affected by many factors, including but not limited to signs of cholinergic deficit, stage of disease, rate of disease progression, presence of apathy, concomitant diseases, and education level . CIs are associated with modest but persistent cognitive benefits over several years and reduced mortality, and both CIs and memantine have demonstrated prolonged time to institutionalization and reduced caregiver burden …”
Section: Disease Treatmentmentioning
confidence: 99%
“…It was also not known whether long-term use would accompany desired outcomes, such as delay in institutionalization. It is now established that response to CIs is complex and affected by many factors, including but not limited to signs of cholinergic deficit, stage of disease, rate of disease progression, presence of apathy, concomitant diseases, and education level . CIs are associated with modest but persistent cognitive benefits over several years and reduced mortality, and both CIs and memantine have demonstrated prolonged time to institutionalization and reduced caregiver burden …”
Section: Disease Treatmentmentioning
confidence: 99%
“…According to the cholinergic hypothesis, degeneration of cholinergic neurons in the basal forebrain results in cognitive dysfunction in AD[ 37 ]. Other conditions that occur via the cholinergic system include amyloid deposition, tau phosphorylation, neuroinflammation, and vascular damage (Pozzi et al [ 38 ], 2022). Acetylcholine, the neurochemical transmitter in the cholinergic synapses, is inactivated by AChE, and to a lesser extent by BuChE.…”
Section: Butyrylcholinesterase and Cognitionmentioning
confidence: 99%
“…However, the development of DMTs has been hindered by undetectable efficacy and the emergence of side effects in clinical trials. Therefore, at present, drug treatment for AD still relies on AChEIs [ 103 ].…”
Section: Neurodegenerative Disorders Associated With Abnormal Vascula...mentioning
confidence: 99%